JP6949832B2 - タンパク質コンジュゲート - Google Patents

タンパク質コンジュゲート Download PDF

Info

Publication number
JP6949832B2
JP6949832B2 JP2018516719A JP2018516719A JP6949832B2 JP 6949832 B2 JP6949832 B2 JP 6949832B2 JP 2018516719 A JP2018516719 A JP 2018516719A JP 2018516719 A JP2018516719 A JP 2018516719A JP 6949832 B2 JP6949832 B2 JP 6949832B2
Authority
JP
Japan
Prior art keywords
protein
conjugate
linker
mmol
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018516719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535195A (ja
JP2018535195A5 (cg-RX-API-DMAC7.html
Inventor
イミリアーノ・クロ
ミケール・コフォード−ハンスン
ヘンリク・スーン・ラミレス−アンデルセン
ニルス・ランゲラン・ヨハンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6949832(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2018535195A publication Critical patent/JP2018535195A/ja
Publication of JP2018535195A5 publication Critical patent/JP2018535195A5/ja
Application granted granted Critical
Publication of JP6949832B2 publication Critical patent/JP6949832B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018516719A 2015-10-01 2016-09-30 タンパク質コンジュゲート Expired - Fee Related JP6949832B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15187937 2015-10-01
EP15187937.6 2015-10-01
PCT/EP2016/073470 WO2017055582A1 (en) 2015-10-01 2016-09-30 Protein conjugates

Publications (3)

Publication Number Publication Date
JP2018535195A JP2018535195A (ja) 2018-11-29
JP2018535195A5 JP2018535195A5 (cg-RX-API-DMAC7.html) 2019-11-07
JP6949832B2 true JP6949832B2 (ja) 2021-10-13

Family

ID=54252136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516719A Expired - Fee Related JP6949832B2 (ja) 2015-10-01 2016-09-30 タンパク質コンジュゲート

Country Status (7)

Country Link
US (1) US11292825B2 (cg-RX-API-DMAC7.html)
EP (1) EP3355931B1 (cg-RX-API-DMAC7.html)
JP (1) JP6949832B2 (cg-RX-API-DMAC7.html)
CN (1) CN108136043B (cg-RX-API-DMAC7.html)
ES (1) ES2985999T3 (cg-RX-API-DMAC7.html)
MA (1) MA43348A (cg-RX-API-DMAC7.html)
WO (1) WO2017055582A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー/エス オリゴマー伸長インスリン−Fcコンジュゲート
MA68842B1 (fr) * 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
EP4241789A4 (en) * 2020-12-08 2025-04-02 Nona Biosciences (Shanghai) Co., Ltd. Protein-drug conjugate and site-specific conjugation method
CN113024669B (zh) * 2021-03-12 2022-06-14 北京华科泰生物技术股份有限公司 含氨基或羧基基团物质标记的rbp抗体、人rbp免疫层析检测试剂盒及其制备方法
CN115819611B (zh) * 2021-12-30 2024-05-28 君合盟生物制药(杭州)有限公司 生长激素融合蛋白及其制备方法和用途
CN115845032B (zh) * 2022-10-28 2026-02-06 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途
WO2025184552A2 (en) * 2024-03-01 2025-09-04 The Scripps Research Institute Dual gip/glp-1 peptide conjugates and methods of use
US20260158159A1 (en) * 2024-07-24 2026-06-11 Eli Lilly And Company Fc-ACYLATED POLYPEPTIDE CONJUGATES

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286509C (cg-RX-API-DMAC7.html)
DE257197C (cg-RX-API-DMAC7.html)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2004524020A (ja) 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
AU2002341215A1 (en) 2001-11-12 2003-05-26 University Of Wales College Of Medicine Growth hormone variations in humans and their uses
GB2384001B (en) 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CA2595695A1 (en) 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life
US20090036353A1 (en) 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
MX2007009906A (es) 2005-02-16 2007-09-25 Novo Nordisk As Derivados de agentes insulinotropicos conjugados con polimeros ramificados estructuralmente bien definidos.
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8492129B2 (en) 2005-12-12 2013-07-23 Innova Biosciences, Ltd. Production of conjugates
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2008052108A2 (en) 2006-10-26 2008-05-02 Centocor Ortho Biotech Inc. Methods for use in human-adapting monoclonal antibodies
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Fc에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
CN106822891A (zh) 2008-06-20 2017-06-13 诺华公司 具有降低的聚集的免疫球蛋白
WO2010001196A1 (en) 2008-07-02 2010-01-07 Koninklijke Philips Electronics N.V. V-spring configuration and end attachment assemblies therefor for use in a personal care appliance
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP5808671B2 (ja) 2008-11-10 2015-11-10 ノヴォ ノルディスク アー/エス 機能グループii莢膜遺伝子クラスターを有しないe.colibl21株
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
EP2494061B1 (en) 2009-10-29 2017-01-25 Janssen Biotech, Inc. Antibody glycosylation variants
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
DK2571510T3 (en) 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
EP2694528A1 (en) 2011-04-05 2014-02-12 Martin-Protean, LLC Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
ES2729643T3 (es) 2013-11-26 2019-11-05 Novartis Ag Métodos para la conjugación de oxima con polipéptidos modificados con cetona
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
CN106068274A (zh) 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
US11279771B2 (en) 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
WO2016133372A2 (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
ES2907651T3 (es) 2015-08-14 2022-04-25 Remegen Biosciences Inc Enlazadores covalentes en conjugados de anticuerpo-fármaco y métodos para obtener y usar los mismos
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー/エス オリゴマー伸長インスリン−Fcコンジュゲート
US20210393745A1 (en) 2018-10-10 2021-12-23 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use

Also Published As

Publication number Publication date
CN108136043A (zh) 2018-06-08
ES2985999T3 (es) 2024-11-08
JP2018535195A (ja) 2018-11-29
WO2017055582A1 (en) 2017-04-06
US11292825B2 (en) 2022-04-05
CN108136043B (zh) 2022-09-06
EP3355931A1 (en) 2018-08-08
EP3355931B1 (en) 2024-06-26
MA43348A (fr) 2018-08-08
US20180282387A1 (en) 2018-10-04
EP3355931C0 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
CN108136043B (zh) 蛋白质缀合物
JP7754361B2 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025023052A (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN104066438B (zh) 抗糖尿病化合物
JP6745218B2 (ja) ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
KR20210020015A (ko) 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
JP6727210B2 (ja) Fgf21誘導体及びその使用
RU2598273C2 (ru) Производные инсулина, содержащие дополнительные дисульфидные связи
JP2012521360A (ja) Kv1.3の選択的かつ強力なペプチド阻害剤
JP2020114234A (ja) Xten共役組成物およびそれを製造する方法
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
TW201446792A (zh) Nav1.7之強效及選擇性抑制劑
US20210393745A1 (en) Oligomer extended insulin-fc conjugates and their medical use
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
KR20230133289A (ko) 화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
US11884711B2 (en) Fusion proteins of GDF15 and use thereof
JP7823234B2 (ja) 長時間作用型成長ホルモン受容体拮抗薬およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210616

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210624

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210922

R150 Certificate of patent or registration of utility model

Ref document number: 6949832

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees